^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ZN-e4

i
Other names: ZN-e4, KP-673
Associations
Trials
Company:
SciClone, Zentalis Pharma
Drug class:
EGFR inhibitor
Related drugs:
Associations
Trials
11ms
A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=34, Completed, Zeno Pharmaceuticals, Inc. | Phase classification: P1/2 --> P1
Phase classification • Metastases
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
|
ZN-e4
2years
A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=34, Completed, Zeno Pharmaceuticals, Inc. | Active, not recruiting --> Completed
Trial completion • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
|
ZN-e4
2years
A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=34, Active, not recruiting, Zeno Pharmaceuticals, Inc. | N=140 --> 34 | Trial primary completion date: Jun 2022 --> Jan 2022
Enrollment change • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
|
ZN-e4
over2years
A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=140, Active, not recruiting, Zeno Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
|
ZN-e4
over5years
Clinical • New P1 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
|
ZN-e4